Short answer
MARAVAI LIFESCIENCES HOLDINGS, INC. (MRVI) filed an 8-K current report with the SEC on November 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q3 2026 financial results announced by Maravai LifeSciences.
MARAVAI LIFESCIENCES HOLDINGS, INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q3 2026 financial results announced by Maravai LifeSciences
- Full results, operating metrics and management commentary in Exhibit 99.1
- Investor focus: quarterly performance trends and updated outlook disclosed in the earnings release
Item EX-99.1 · Exhibit EX-99.1
- Q3 revenue $45.9M, up 10.1% YoY, with TriLink up 11.8% and Cygnus up 7.5%
- mRNA revenue rose 28%, while four Discovery customers transitioned to clinical-stage GMP, supporting future commercial demand
- Adjusted EBITDA improved to $5.8M from $(10.8)M, though GAAP net loss remained $(24.0)M
- Nine-month revenue up 20.1% to $163.1M, including $14.3M of COVID CleanCap orders and 12.9% base TriLink growth excluding them
- 2026 guidance raised: revenue $212.0M-$216.0M and Adjusted EBITDA $40.0M-$42.0M, versus prior ranges of $205.0M-$215.0M and $33.0M-$35.0M
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other MARAVAI LIFESCIENCES HOLDINGS, INC. 8-K filings
Get the next MRVI 8-K as it lands
Follow MRVI for push alerts, or ask the research agent what this filing means.